Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis.

Trial Profile

Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Dec 2016

At a glance

  • Drugs Ceftazidime (Primary) ; Tobramycin (Primary) ; Ciprofloxacin
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Therapeutic Use
  • Acronyms TORPEDO-CF
  • Most Recent Events

    • 17 Dec 2016 Last checked against European Clinical Trials Database record.
    • 01 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 05 Dec 2015 Accrual to date is 86% according to the United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top